Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
TheFly reported on June 22 that H.C. Wainwright initiated coverage of AGMB with a Buy rating and assigned a $35 price target.
Agomab Therapeutics Nv (AGMB)
This company is not actively trading or the ticker does belong to another company in our database now.
News See All
8 Best Up and Coming Pharmaceutical Stocks to Buy Now
Investors looking for substantial potential without making a sizable initial investment continue to be drawn to inexpensive stocks.
7 Best Strong Buy European Stocks to Invest In
European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.
Hedge Fund Resource Center